In reality no real news at all just rehashing the previous two announcements regarding CE Mark. The only difference from Nov 19 release are the words formally submitted versus, presented plans.
"In a subsequent meeting with BSI held on 14November, the Company presented its Post-Market Surveillance (PMS) Plan and Post-Market Clinical Follow-Up (PMCF) programme for the OncoSil™ device. The plans outline how the device would be rolled out by OncoSil into the European Marketpost CE Mark approval. OncoSil has since formally submitted both plans to the BSI, with the CE Mark review now in its final phase. The Company would expect the final determination in the coming weeks.
Amazing how the price can move 14% on the basis of that one word ;-)
Ann: Appendix 4C - quarterly, page-2
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.002(22.2%) |
Mkt cap ! $37.38M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.2¢ | 1.0¢ | $271.4K | 26.46M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 7073500 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 75694 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |